PT  - JOURNAL ARTICLE
AU  - Beyzadeoglu, Murat
AU  - Arpaci, Fikret
AU  - Surenkok, Serdar
AU  - Ozyigit, Gokhan
AU  - Oysul, Kaan
AU  - Caglar, Kayser
AU  - Ataergin, Selmin
AU  - Yenicesu, Mujdat
AU  - Kaya, Ayper
TI  - Acute renal toxicity of 2 conditioning regimens in patients undergoing autologous peripheral blood stem-cell transplantation. Total body irradiation-cyclophosphamide versus ifosfamide, carboplatin, etoposide
DP  - 2008 Jun 01
TA  - Saudi Medical Journal
PG  - 832--836
VI  - 29
IP  - 6
4099  - http://smj.org.sa/content/29/6/832.short
4100  - http://smj.org.sa/content/29/6/832.full
SO  - Saudi Med J2008 Jun 01; 29
AB  - OBJECTIVE: To compare acute renal toxicity of 2 conditioning regimens of total body irradiation/cyclophosphamide TBI-Cy and Ifosfamide, Carboplatin, and Etoposide ICE.METHODS: Between August 1996 and February 2004, patients treated with autologous peripheral stem cell transplantation in the Department of Medical and Radiation Oncology, Gulhane Military Medical School, Ankara, Turkey with 2 different conditioning regimens was comparatively analyzed for acute renal toxicity in the early post-transplant period. Forty-seven patients received ICE regimen with 12 g/m2; 1.2 g/m2; and 1.2 g/m2 divided to 6 consecutive days, whereas 21 patients received 12 Gy TBI 6 fractions twice daily in 3 consecutive days and 60 mg/m2/day cyclophosphamide for 2 days.RESULTS: Sixty-eight patients were evaluated in this study. There was no significant difference in baseline renal function between patients in the ICE and TBI-Cy groups. Eleven patients developed nephrotoxicity 23.4% in the ICE group while one patient 4.8% in the TBI-Cy group developed nephrotoxicity p=0.06. Five out of 11 patients developing nephrotoxicity in ICE group required hemodialysis and subsequently 4 8.5% of them died. In contrast, one patient 4.8% died due to nephrotoxicity despite hemodialysis in the TBI-Cy arm.CONCLUSION: This study reveals that the TBI-Cy conditioning regimen seems no more nephrotoxic than an ICE regimen particularly in patients who had used cisplatin prior to transplantation.